6612.TWO Icares Medicus Inc
- Market cap
- TWD 3.22B
- P/E
- 38.3x
- P/B
- 1.72x
- ROE
- 7.7%
- Dividend yield
- 0.40%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6612.TWO undervalued?
Graham number6612.TWO trades 70.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Icares Medicus Inc fundamental analysis
No fundamental analysis for Icares Medicus Inc yet.
Icares Medicus Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Icares Medicus Inc
ICARES Medicus, Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of ophthalmic medical devices in Taiwan, the United States, United Kingdom, Japan, Spain, China, Germany, and internationally. The company is also involved in the manufacturing, sales, and service of intraocular lenses (IOLs) and its implantation systems for use in treating cataracts, myopia, farsightedness, presbyopia, or astigmatism, as well as related techni…
Full company profileIcares Medicus Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Icares Medicus Inc annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 266M | 329M | 419M | 363M | 394M | 512M | 605M | 860M | 1.13B | 1.29B |
| Gross Profit | 205M | 235M | 332M | 292M | 323M | 417M | 482M | 600M | 668M | 696M |
| Operating Income | 63.5M | 88.8M | 118M | 73.5M | 77.2M | 146M | 131M | 129M | 128M | 148M |
| EBITDA | 82.3M | 111M | 141M | 104M | 106M | 174M | 174M | 272M | 242M | 352M |
| Net Income | 31.2M | 70.5M | 81.0M | 51.9M | 58.6M | 129M | 97.7M | 103M | 51.2M | 145M |
| EPS | 1.03 | 2.12 | 2.40 | 1.52 | 1.72 | 3.74 | 2.79 | 1.98 | 0.98 | 2.80 |
| Balance Sheet | ||||||||||
| Total Assets | 401M | 617M | 792M | 848M | 966M | 1.04B | 1.91B | 3.01B | 3.18B | 3.20B |
| Total Liabilities | 64.9M | 46.0M | 139M | 146M | 145M | 106M | 240M | 1.25B | 1.21B | 1.21B |
| Shareholders' Equity | 336M | 570M | 623M | 666M | 747M | 879M | 1.58B | 1.66B | 1.83B | 1.90B |
| Cash & Short-term Investments | 219M | 399M | 310M | 281M | 374M | 427M | 968M | 440M | 459M | 350M |
| Total Debt | - | - | - | 23.3M | 17.5M | 6.16M | 122M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 45.5M | 63.2M | 88.8M | 71.4M | 38.6M | 129M | -25.8M | -48.5M | -58.8M | 91.7M |
| Capital Expenditure | 8.44M | 6.08M | 93.4M | 11.2M | 6.48M | 34.0M | 76.5M | 157M | 53.5M | 53.3M |
| Free Cash Flow | 36.7M | 54.6M | -5.62M | 60.2M | 32.1M | 94.9M | -102M | -205M | -112M | 38.4M |
| Ratios | ||||||||||
| ROE | 9.3% | 12.4% | 13.0% | 7.8% | 7.8% | 14.7% | 6.2% | 6.2% | 2.8% | 7.7% |
| ROA | 7.8% | 11.4% | 10.2% | 6.1% | 6.1% | 12.4% | 5.1% | 3.4% | 1.6% | 4.5% |
| Net Profit Margin | 11.7% | 21.4% | 19.3% | 14.3% | 14.9% | 25.2% | 16.1% | 12.0% | 4.5% | 11.2% |
| Debt to Equity | - | - | - | 0.03x | 0.02x | 0.01x | 0.08x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Icares Medicus Inc dividends
- Dividend yield
- 0.40%
- Forward dividend
- 0.30 TWD
- Payout ratio
- 25.2%
- Ex-dividend date
- Aug 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 12.9M | 0.25 | 25.2% |
| 2024 | TWD 7.83M | 0.15 | 7.6% |
| 2023 | TWD 34.2M | 0.98 | 35.0% |
| 2022 | TWD 17.0M | 0.49 | 13.2% |
| 2021 | TWD 3.40M | 0.10 | 5.8% |
| 2020 | TWD 16.9M | 0.50 | 32.5% |
| 2019 | TWD 16.8M | 0.50 | 20.7% |
| 2018 | TWD 15.1M | 0.46 | 21.5% |
| 2017 | TWD 15.1M | 0.50 | 48.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1100.7699:1000 on Aug 26, 2026.
Who owns Icares Medicus Inc
- Insiders 54.89%
- Institutions 0.23%
- Public & others 44.88%
- Shares outstanding 47.0M
- Free float 23.6M
Icares Medicus Inc company profile
- Company name
- Icares Medicus Inc
- Ticker
- 6612.TWO
- ISIN
- TW0006612005
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- No. 16, Shengyi Road, Zhubei, Taiwan
- Phone
- 886 3 657 9530
- Website
- icaresmedicus.com
About Icares Medicus Inc
ICARES Medicus, Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of ophthalmic medical devices in Taiwan, the United States, United Kingdom, Japan, Spain, China, Germany, and internationally. The company is also involved in the manufacturing, sales, and service of intraocular lenses (IOLs) and its implantation systems for use in treating cataracts, myopia, farsightedness, presbyopia, or astigmatism, as well as related technical services. In addition, it offers artificial crystal products; and lubricious implantable and invasive high-end nanomedicine material. Further, the company engages in molding, mold design, and development; production of medical devices and electronic plastic products; and distribution of ophthalmic medical equipment. ICARES Medicus, Inc. was incorporated in 2011 and is based in Zhubei, Taiwan.
Icares Medicus Inc management
6- Bing Chun ChenGeneral Manager
- Ms. Tan-Li ChenVP and Head of Finance & Accounting Department
- Junming LinVice President of R&D and Operations
- Mr. Wen-Chu TsengChief R&D Officer & Director
- Mr. Carl Robert CummingsPresident of Major Subsidiary
- Mr. Ying-Zong YanDirector